Pipeline

Deep product pipeline of T2MR® applications in development

T2 Biosystems has multiple applications currently in development that are designed to enable breakthroughs in providing more rapid and accurate therapy to patients. All applications are focused on critical unmet needs in healthcare where solutions can serve a dual role: saving lives while reducing costs. Because T2 Magnetic Resonance (T2MR) has the advantage of detecting directly from patient samples, there is an opportunity for significant clinical advancements and market impact.

Product Pipeline Highlights 

In addition to our FDA-cleared T2Bacteria® PanelT2Candida® Panel and T2Dx® Instrument, new products in the pipeline include additional sepsis, hemostasis and Lyme disease applications.

Sepsis: T2 Biosystems and Allergan have partnered to develop a panel to detect gram-negative resistance markers. T2 also has a research use only panel for Candida auris that can be used for blood, patient skin and environmental samples.

Lyme: T2 Biosystems and Canon U.S. Life Sciences have partnered to develop a rapid diagnostic for Lyme disease, the T2Lyme™ Panel.

Hemostasis: The T2 hemostasis pipeline includes the T2HemoStat™ Panel, which provides comprehensive hemostasis profiling for trauma patients at the point of care, and the T2Plex™ Instrument, a compact, fully integrated instrument for providing rapid hemostasis measurements at the point of care. The T2Plex Instrument is also available for research use as an open system for researcher-designed tests.

……………………………………….

1. This page contains T2's future goals and aspirations, which constitute forward-looking statement that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. See "Forward-Looking Statements" and the factors discussed under Item 1A. "Risk Factors" in the company's most recent Annual Report on Form 10-K for the prior fiscal year, filed with the U.S. Securities and Exchange Commission, or SEC, and other filings the company makes with the SEC from time to time.
The T2Dx Instrument, T2Bacteria Panel, and T2Candida Panel have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.